Sort   by:  
 Page size 
UnknownTargeting ON-bipolar cells by AAV gene therapy stably reverses LRIT3-congenital stationary night blindness.
Not available
S-EPMC9060458 | biostudies-literature
UnknownGuadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Not available
S-EPMC11103175 | biostudies-literature
UnknownEnasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Not available
S-EPMC10644040 | biostudies-literature
UnknownSmoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study.
Not available
S-EPMC11380676 | biostudies-literature
UnknownDivergent mutational processes distinguish hypoxic and normoxic tumours.
Not available
S-EPMC7002770 | biostudies-literature
UnknownFactors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Not available
S-EPMC8734323 | biostudies-literature
UnknownAn adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
Not available
S-EPMC8758206 | biostudies-literature
UnknownAdding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Not available
S-EPMC7616360 | biostudies-literature
UnknownDesign and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program.
Not available
S-EPMC9835888 | biostudies-literature
UnknownRisk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
Not available
S-EPMC8945306 | biostudies-literature
Sort   by:  
 Page size